NAD+ Telehealth Providers and Pricing

Direct answer

RightFit’s current telehealth NAD+ research covers compounded prescription programs using several routes, including subcutaneous injections, nasal sprays, and an oral tablet. The provider programs are not one standardized NAD+ product. Route, formulation, supply, plan length, included services, and price vary, so the comparison keeps each formulation separate and does not treat provider wellness claims as established outcomes.

Current NAD+ telehealth market snapshot

Current published NAD+ provider programs and pricing

The current catalog includes three route categories

The current structured dataset contains 11 published NAD+ injection programs, five nasal-spray programs, and one oral-tablet program. Those counts describe provider programs, not unique pharmacies or equivalent products. A provider can offer more than one formulation and appear in more than one route category.

The injection category currently has the broadest provider coverage. Nasal programs are also advertised by several providers, while oral NAD+ is less common in the current published set.

Route is a product attribute, not a medical ranking

RightFit records subcutaneous injection, intranasal spray, and oral tablet as separate routes because they are different formulations and commercial programs. A lower price for one route does not establish that it is clinically equivalent to, safer than, or more appropriate than another route.

Those clinical questions require product-specific evidence and licensed healthcare guidance; this page stays focused on what providers currently advertise and charge.

Provider marketing claims need separate evidence

NAD+ telehealth pages can use marketing language about energy, recovery, aging, cellular function, or performance. RightFit does not adopt those claims merely because they appear on provider pages. The fact that a provider sells a prescription program is evidence of the commercial offer, not proof of every advertised wellness outcome.

This separation lets RightFit use provider pages for price and program facts while reserving clinical claims for independent evidence review.

FDA has raised sterile-compounding concerns involving NAD+

FDA has warned compounders to use ingredients suitable for sterile compounding and specifically noted awareness of food-grade nicotinamide adenine dinucleotide (NAD+) being used to make intravenous products. FDA stated that food-grade ingredients are not suitable for sterile compounding without appropriate processing because of contamination and endotoxin risks.

That warning is regulatory and compounding context; it does not mean every NAD+ telehealth program has the same ingredient-source problem. RightFit should therefore report the FDA warning accurately without converting it into a blanket accusation against providers whose specific pharmacy sourcing has not been independently established.

Injection programs use several pricing structures

The current dataset includes injection programs with ordinary monthly pricing, lower three-, six-, or twelve-month equivalents, and programs with separate memberships. Amble, Belle, Effecty, Gimme Care, and Yucca Health are among the providers publishing multi-month structures.

RightFit preserves the ordinary recurring price and the prepaid promotional observations separately so the lowest effective monthly number does not replace the month-to-month price.

Nasal-spray programs should stay in their own comparison group

Providers such as 10Rx, Effecty, TRAVA, Shed, and others in the tracked set advertise NAD+ nasal-spray programs. Those prices should not be mixed with injection prices without labeling route because the formulation, supply, and use instructions can differ.

Oral NAD+ is another separate formulation

The current catalog includes a compounded oral NAD+ tablet program. It remains separate from nasal and injection records. A broad provider headline that simply says “NAD+” is not enough to assume which formulation is being sold.

Membership structure can change the practical total

Some providers include clinical access or membership in the displayed NAD+ price. Others publish a medication amount plus a separate membership. IViM Health and NavioMD, for example, currently have structured records in which a separate recurring fee applies alongside the NAD+ medication price.

RightFit keeps those fees outside the medication amount so the provider’s original price remains traceable while the customer can still see the required recurring components.

Shipping is often included, but not universally verified

Many current NAD+ price rows explicitly include shipping, while some provider pages leave the shipping field less clear. RightFit marks shipping included only when the provider source states it. Silence remains unknown.

Multi-month pricing needs the commitment attached

A lower annual or six-month effective rate can be attractive, but the amount is tied to a longer purchase commitment. The comparison should preserve the term and, when available, the amount due up front rather than showing only the smaller monthly equivalent.

State coverage is not inferred from the longevity category

A provider may offer weight-management treatment nationally while its NAD+ program has different pharmacy or state availability. RightFit only publishes state coverage for the exact provider program when current first-party evidence supports it.

What to compare across NAD+ providers

• Exact formulation and route
• Compounded preparation status
• Normal recurring medication or program price
• Multi-month or promotional price
• Required membership or subscription fees
• Whether clinician access and shipping are included
• Supply duration and plan term
• Cancellation and renewal terms when published
• Program-level state availability when verified
• Provider source and last-verification date

Why a cheap route should not become a treatment recommendation

A lower injection, nasal, or oral price is a commercial fact, not evidence that the route is clinically preferable. RightFit does not use price to rank medical suitability and does not infer comparative effectiveness from the provider catalog.

How provider rows can change

NAD+ catalogs can change when a provider changes formulations, pharmacy partners, supply amounts, or plan lengths. A page can continue to say “NAD+” while the actual route or commercial terms change. RightFit attaches verification dates and formulation records so those changes can be updated precisely.

A provider can offer several NAD+ formats under one brand

Current provider catalogs show why NAD+ needs formulation-level modeling. A company can advertise injections, nasal spray, and oral options on the same longevity page, with different prices and supply structures for each. RightFit therefore treats each route as a separate provider-treatment record rather than assigning one NAD+ price to the provider as a whole.

Shed’s current product page is a clear example: its NAD+ offering is presented in injection, nasal-spray, and oral formats, and the listed starting amounts are not identical across the routes. That is a commercial reason to keep route-specific rows even before any clinical comparison is considered.

First-party product pages are stronger than generic longevity pages

Many telehealth companies maintain a general longevity catalog plus dedicated treatment pages and promotional landing pages. RightFit favors the most specific current provider-owned source for the formulation, price, and plan term. A general page can establish that a provider offers NAD+, but a dedicated product page is usually better evidence for the route, current price, supply period, and included services.

If the general catalog and a product-specific page conflict, the discrepancy should be reviewed rather than averaged. A temporary campaign can coexist with a standard price, and the lower figure may require a code, first-month condition, or multi-month purchase.

Promotional longevity claims stay separate from product facts

NAD+ pages often make broad claims around energy, focus, aging, recovery, cellular health, or performance. RightFit can quote or summarize those claims as provider marketing when relevant, but it should not convert them into a neutral description of what the product is proven to do. The verified provider facts are the existence of the program, formulation, route, price, billing terms, and stated inclusions.

That separation also protects the comparison from rewarding more aggressive marketing. A provider with stronger sales copy does not receive a better position in RightFit’s factual catalog simply because its page makes more outcome claims.

State and pharmacy coverage can differ by formulation

A provider’s ability to offer one longevity product in a state does not automatically prove that every NAD+ route is available there. The dispensing pharmacy, prescription requirements, provider licensure, and internal product policy can vary by formulation. RightFit therefore requires program-level evidence before publishing state coverage.

What makes a provider record comparison-ready

• A current provider-owned page identifying the NAD+ product.
• The exact route and formulation when disclosed.
• Preparation type and prescription status.
• Current standard and promotional pricing kept separate.
• Billing period and any prepaid commitment.
• Verified membership, clinician-access, and shipping terms.
• Program-specific state evidence when available.
• A verification date recent enough to detect catalog changes.

Bottom line

The current NAD+ telehealth market is a set of compounded prescription programs with different routes and billing models, not one standardized product. RightFit separates injection, nasal, and oral formulations; normal and prepaid pricing; memberships; inclusions; and regulatory context while keeping provider wellness claims outside the factual pricing comparison.